Brief: Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance

Tempest Therapeutics

09/06/2022 13:02

June 9 (Reuters) - Tempest Therapeutics Inc  TPST.O :
    * TEMPEST PROVIDES ASCO KOL FEEDBACK ON TPST-1120 CLINICAL
RESULTS
AND UPDATED FINANCIAL GUIDANCE
    * TEMPEST THERAPEUTICS - RECIST RESPONSES SEEN WITH
TPST-1120
COMBINED WITH ANTI-PD1 THERAPY IN PATIENTS WHO PREVIOUSLY
PROGRESSED ON ANTI-PD1/PDL1 THERAPY
    * TEMPEST THERAPEUTICS INC - POTENTIAL BIOMARKER FOR PATIENT
RESPONSIVENESS TO TPST-1120 IDENTIFIED AND WILL BE FURTHER
EXPLORED
    * TEMPEST THERAPEUTICS INC - TPST-1120 DEMONSTRATED ABILITY
TO
REPROGRAM TME IN A TUMOR TYPE REFRACTORY TO ANTI-PD1 WITH LOW
TUMOR MUTATION BURDEN
    * TEMPEST THERAPEUTICS INC - TPST-1120 DEMONSTRATED
MONOTHERAPY
CLINICAL BENEFIT IN PATIENTS WITH LATE-LINE ADVANCED,
POOR-PROGNOSIS CANCERS
    * TEMPEST THERAPEUTICS INC - TPST-1120 WAS WELL TOLERATED AS
BOTH
A MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB
    * TEMPEST THERAPEUTICS INC - CASH AND CASH EQUIVALENTS ARE
CURRENTLY EXPECTED TO BE SUFFICIENT TO FUND ITS CURRENT
OPERATING PLANS INTO Q1 OF 2024

Source text for Eikon:  ID:nGNX9kwKGt 
Further company coverage:  TPST.O 

 ((reuters.briefs@thomsonreuters.com;))